LenioBio

  🚀 Last Chance: Webinar Tomorrow on Accelerating Vaccine Development! 🗓️ July 17th @17:00 CEST (11:00 ECT) Join us for an insightful webinar with Jorge Armero Giménez Armero Gimenez on "Accelerating Vaccine Development with Advanced Protein Expression Technology." Key Highlights: ⚡ Rapid protein production 💪 Enhanced immune responses 🧪 Scalable manufacturing Don't miss out! Save your spot now! 🔗 Register Now: https://lnkd.in/d7gJBjRY #VaccineDevelopment #VLPs #Biotech #ProteinExpression

🚀 Just One Week Left! Join us on July 17th for an insightful webinar featuring Jorge Armero Giménez, presenting "Accelerating Vaccine Development with an Advanced Protein Expression Technology" In this webinar, Jorge will cover how virus-like particles (VLPs) are revolutionizing vaccine development. He will share his experience with our cell-free expression platform for screening and scaled manufacture of core VLPs and discuss how VLPs can be adapted for emerging situations. 🔗 Don’t miss out, register now 👉🏼 https://lnkd.in/d7gJBjRY #VaccineDevelopment #VLPs #Biotech #ProteinExpression

🚀 Webinar Alert: Transforming Vaccine Development with VLP Technology! 🗓️ Save the Date: July 17th Join us for an insightful webinar featuring Jorge Armero Gimenez, presenting "Accelerating VLP Vaccine Development with an Advanced Protein Expression Technology" Virus-like particles (VLPs) are revolutionizing vaccine development, offering robust immune responses, enhanced safety, and greater stability compared to traditional vaccines. In this webinar, Jorge will share his experience with a cell-free expression platform for the screening and scaled manufacture of core VLPs. 🔬 Key Highlights: ⚡ Rapid production and self-assembly of VLPs 💪 Simple VLP adaptation for specific pathogens 🧪 Scaled production to dosage-relevant yields Don’t miss this opportunity to dive deep into the future of vaccine development! 🔗 Register now: https://cstu.io/da0c03 #VaccineDevelopment #Biotec

🌟 Breaking News🌟Cell-free synergies to accelerate pandemic response We are pleased to announce that Touchlight, the leader in enzymatic DNA production, will participate in our recently announced CEPI (Coalition for Epidemic Preparedness Innovations)-funded project to accelerate pandemic response. This collaboration leverages Touchlight’s rapid enzymatic doggybone DNA (dbDNA™) to speed-up vaccine development and production using LenioBio’s groundbreaking plant-based, cell-free ALiCE® technology. Together, we aim to meet CEPI’s 100 Days Mission to develop vaccines against novel pathogens within 100 days. With ALiCE®'s ability to produce vaccine-relevant proteins in just 48 hours and Touchlight’s dbDNA offering a fast, scalable, and resilient DNA supply, we are poised to establish a seamless end-to-end manufacturing process for pandemic preparedness. “We’re thrilled to partner with Touchlight and explore the synergy between our innovative technologies to achieve unprecedented speed in scaled protein production,” says our CEO Andre Goerke. For more details, check out the full press release: https://lnkd.in/eCjFaiwG #Biotech #VaccineDevelopment #PandemicResponse #Innovation #CellFreeTechnology

New Study Shows ALiCE Matches CHO in Producing Functional Adalimumab We are pleased to share our latest findings on the functionality of cell-free produced adalimumab, presented in our poster: "First insights into functionality of cell-free produced adalimumab in comparison to Humira®." We selected the monoclonal antibody adalimumab (Humira®) for a comparability study between the ALiCE® eukaryotic cell-free and the CHO protein expression systems. Our study demonstrated: 🔄 Batch-to-Batch Consistency: ALiCE-produced adalimumab shows remarkable consistency across batches at both 100 mL and 1 L scales. 🔬 Highly Comparable Protein: ALiCE-produced adalimumab is highly comparable to CHO-produced protein in functionality, physiochemistry, disulfide bond formation, and single-dose pharmacokinetic analysis. 💡 Key Insight: Although glycosylation patterns differ, the N-glycan profile of ALiCE-produced adalimumab does not impact its half-life. What This Means: 🌟 ALiCE can produce therapeutic proteins with exceptional quality, functionality, and reproducibility. 🌟 Eukaryotic cell-free protein synthesis with ALiCE delivers proteins of comparable quality to traditional cell-based methods in hours instead of weeks. Congratulations to the authors: Zulfaquar A. Arfi, Juliane Norf, Hannes Jürgens, Robin Roentgen, Yannick Flaskamp, Nidhi Shah, Harendra Mahto, Maja Lieven, and Ricarda Finnern. Check out the detailed poster for more insights 👇🏻 #ProteinExpression #ALiCE #DrugDevelopment #Adalimumab #CellFreeSynthesis #ComparativeStudy

🚀 Exciting news: You can now get our ALiCE® technology faster in the US! We are thrilled to announce our strategic partnership with Labscoop to enhance access to LenioBio’s groundbreaking ALiCE® technology across North America. By partnering with leading life sciences marketplace, Labscoop, we can now serve our growing number of US customers with: ✨ Faster Shipping: Reduced wait time for products. 💸 Cost Savings: Benefit from reduced shipping costs. 🔒 Reliability: Our partnership ensures consistent and reliable service, supported by exceptional US-based customer support. LenioBio’s ALiCE® technology is revolutionizing protein production, enabling rapid expression of complex proteins and accelerating research and development projects. Together with Labscoop, we are dedicated to empowering researchers, advancing scientific discovery, and driving forward biotherapeutic innovation. Order in the US now 👉🏼 https://lnkd.in/e6ybQSyY Check out the full press release: https://lnkd.in/gFC-uv8t #Biotech #ProteinExpression #ResearchTools #LifeSciences

🚨 Final Reminder: Webinar Tomorrow! 🚨 Our webinar, "A Scalable Protein Production Technology to Accelerate Biotherapeutic Development," is just one day away! Join us tomorrow, June 19th, to explore how our innovative system is transforming the landscape of vaccine and biotherapeutic development. In this webinar, Dr. Ricarda Finnern will delve into a rapid high-throughput screening protocol and present first in-animal pharmacokinetics data for a therapeutic antibody, providing crucial insights into the quality and safety of proteins produced with our technology. Last chance to secure your spot 👉🏼 https://lnkd.in/eRCEUBab This is your last chance to join us on this journey to expedite the translation of scientific discoveries into groundbreaking medical solutions. #Biotherapeutics #ProteinExpression #WebinarReminder

🚀 Discover the Future of Biotherapeutic Development with ALiCE! 🌟 As biotherapeutic modalities become more complex, traditional cell-based platforms struggle to keep pace. ALiCE, our eukaryotic cell-free protein expression system, is here to transform the process. Why Choose ALiCE? 🤔 ✅ Access novel targets with ease ✅ Achieve high yields of complex targets ✅ Rapid high-throughput expression of lead candidates ✅ Simple scale-up for characterization ✅ Accelerate design-make-test-analyze cycles ✅ Efficient scale-up for subsequent steps From target identification to lead optimization, ALiCE streamlines workflows and boosts success rates, bringing innovative therapies to market faster. Learn more about the ALiCE advantage and start your discovery journey today 👇🏻 #Biotech #Innovation #Biotherapeutics #DrugDevelopment #ProteinExpression #Healthcare #ALiCE #Research #Pharmaceuticals #BioTechRevolution

📢 Calling all biotech enthusiasts: Just one week left until our exciting webinar, "A Scalable Protein Production Technology to Accelerate Biotherapeutic Development". Join us on June 19th to gain a comprehensive understanding of how this innovative system accelerates the development of vaccines and biotherapeutics. Dr. Ricarda Finnern, our Chief Scientific Officer, will provide detailed insights into a rapid high-throughput screening protocol and share first in-animal pharmacokinetics data obtained with a therapeutic antibody. These insights will shed light on the quality and safety profile of proteins produced using our platform. Secure your spot now and be part of the future of biotechnology 👉🏼 https://lnkd.in/eRCEUBab Don't miss out on this opportunity to revolutionize your approach to biotherapeutic development. #Biotherapeutics #ProteinExpression #WebinarReminder

🚀 LenioBio supports breakthrough in protein expression! Congratulations to the authors (Alex Snow et. al.) of a groundbreaking study that achieved a milestone in cancer research by synthesizing the oncogenic fusion protein, FGFR3-TACC3, using the ALiCE cell-free protein expression system. Overcoming the challenges of producing receptor tyrosine kinases, this method enabled the generation of fully functional proteins in just 48 hours. This advancement accelerates research into oncogenic RTKs and promises to expedite the development of targeted cancer treatments. 🔬 Key Findings: 💫 Successful Protein Production: The study demonstrated the capability of ALiCE microsomes to synthesize functional FGFR3-TACC3, a significant leap forward in protein expression. 💡 Innovative Solubilization: The researchers utilized SMA lipid particles for efficient extraction of membrane protein complexes, preserving their structural integrity and activity. 🎖 Exceptional Protein Quality: Functional assays show high-quality protein output, eliminating the need for extensive optimization. The study highlights the enabling and revolutionary potential of cell-free systems in advancing cancer research and treatment development. Check out the full study 👉 https://lnkd.in/epavJUzY